· Published by Health Canada · Official notice
| Product Name | Product Code | DIN | Lot Numbers/ Expiration Dates | Market Authorization Holder | Package Size |
|---|---|---|---|---|---|
| 0.9% Sodium Chloride Injection, USP | JB1323 | 00060208 | See Appendix A | Baxter Corporation | 500 mL |
| Lactated Ringer’s Injection, USP | JB2323 | 00061085 | See Appendix A | Baxter Corporation | 500 mL |
Intravenous bags of Baxter’s 0.9% Sodium Chloride Injection, USP 500 mL and Lactated Ringer’s Injection, USP 500 mL from certain lots have the potential to leak when administered under pressure infusion due to a weak seal formation.
Affected lots are not being recalled to prevent a shortage of these medically necessary products.
Leakage from the bags could:
lead to contamination of the solution and may result in a serious blood infection. Patients with an infection of the blood may develop a fever, low blood pressure, or an altered level of consciousness. Blood infections may be life-threatening in both adults and children.
result in an inaccurate amount of medication being delivered when other medications have been mixed into the 0.9% Sodium Chloride Injection, USP 500 mL and Lactated Ringer’s Injection, USP 500 mL as part of routine treatments.
expose healthcare professionals or patients handling the bags to hazardous medications (e.g., cytotoxic chemotherapeutic drugs) when these medications have been added to the bags.
Healthcare professionals including physicians, nurses, pharmacists, and other medical and support personnel including home healthcare agencies involved in the administration and handling of 0.9% Sodium Chloride Injection, USP 500 mL and Lactated Ringer’s Injection, USP 500 mL products.
Intravenous bags of Baxter’s 0.9% Sodium Chloride Injection, USP 500 mL and Lactated Ringer’s Injection, USP 500 mL from certain lots have the potential to leak when administered under pressure infusion.
lead to contamination of the solution which may result in a serious blood infection.
result in an inaccurate amount of medication being delivered when other medications have been mixed into the 0.9% Sodium Chloride Injection, USP 500 mL and Lactated Ringer’s Injection, USP 500 mL.
expose healthcare professionals or patients handling the bags to hazardous medications (e.g., cytotoxic chemotherapeutic drugs) when these medications have been added to the bags.
Do NOT administer products from affected lots (see Appendix A) under pressure infusion.
Regardless of the lot, prior to administration, tear the overwrap (outer bag) down the side at the slit and remove the inner bag. Inspect the bag for low fill volume and for leaked fluid in the space between the overwrap and inner bag. Check for minute leaks by squeezing the inner bag firmly.
If any leakage is observed, the bag should be discarded due to the potential risk of contamination.
Monitor for leakage from the bag during treatment and stop using if leakage is observed. In the affected lots, leaks are more likely to be found in the area highlighted in the photo in Appendix B.
Gloves should be worn when handling the bags to avoid exposure to any hazardous medications that may have been added to the bags.
0.9% Sodium Chloride Injection, USP (DIN 00060208) is indicated as a source of water and electrolytes. It can also be used as a vehicle or diluent for compatible products for parenteral administration, or for use as a priming solution in hemodialysis procedures.
Lactated Ringer’s Injection, USP (DIN 00061085) is indicated as a source of water and electrolytes or as an alkalinizing agent.
Baxter identified the cause of the leakage of the 500 mL intravenous bags as a weak seal formation due to inappropriate manufacturing equipment set-up. Baxter has implemented corrective actions to prevent reoccurrence. There have been no reports of adverse events to date for the affected lots.
Products from the affected lots were distributed by Baxter Corporation in Canada between May 21, 2021 and March 01, 2022.
Do NOT use the bags from affected lots in treatments where pressure is applied to the bags, as fluid may leak out.
If you see any fluid leakage from the bags before or during treatment, stop using the product as there may be a potential risk of contamination and consult your healthcare professional.
Gloves should be worn when handling the bag to avoid exposure to any toxic drugs (such as some cancer drugs) that may have been added to the fluid in the bags.
If you use these products with pressure, and you have product from an affected lot, do NOT use the bags and consult your healthcare professional to obtain a replacement product as soon as possible.
Consult with your healthcare professional if you have used product from an affected lot, or are unsure and have questions or concerns about your health.
Bags of 0.9% Sodium Chloride Injection, USP 500 mL and Lactated Ringer’s Injection, USP 500 mL from the affected lots should NOT be used in pressurized intravenous lines due to the potential for product leaks.
Regardless of the lot, prior to administration, tear the overwrap (outer bag) down the side at the slit and remove the inner bag. Inspect the bag for low fill volume and for leaked fluid in the space between the overwrap and inner bag. Check for minute leaks by squeezing the inner bag firmly
If any leakage is observed, the bag should be discarded due to the potential risk of contamination.
Monitor for leakages from the bag during treatment and stop using if leakage is observed. Potential leakages may not be easily identified without the application of pressure over time. In the affected lots, leaks are more likely to be found in the area shown in Appendix B.
Gloves should be worn when handling the bags to avoid exposure to any hazardous medications that may have been added to the bags.
Health Canada is communicating this important safety information to healthcare professionals and Canadians via the Recalls and Safety Alerts Database on the Healthy Canadians Web Site. This communication will be further distributed through the MedEffect™ e-Notice email notification system.
Health Canada has directed Baxter Corporation, the market authorization holder for 0.9% Sodium Chloride Injection, USP 500 mL and Lactated Ringer’s Injection, USP 500 mL, to ensure that they inform all impacted healthcare professionals, patients and personnel administering or handling these products.
Health Canada is monitoring the company’s implementation of any additional corrective and preventative actions. If additional safety information is identified, Health Canada will take appropriate action and inform Canadians as needed.
Health Canada’s ability to monitor the safety of marketed health products depends on healthcare professionals and consumers reporting adverse reactions and medical device incidents. Any case of product-related adverse reactions, including blood infections, or other serious or unexpected adverse reactions in patients receiving 0.9% Sodium Chloride Injection, USP 500 mL and Lactated Ringer’s Injection, USP 500 mL should be reported to Baxter Corporation or to Health Canada.
Baxter Corporation
7125 Mississauga Rd
Mississauga, ON L5N 0C2
To correct your mailing address or fax number, contact Baxter Corporation at fca_canada@baxter.com
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
Calling toll-free at 1-866-234-2345; or
Visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.
For other health product inquiries related to this communication, contact Health Canada at:
Health Product Compliance Directorate, Regulatory Operations and Enforcement Branch
E-mail: hpce-cpsal@hc-sc.gc.ca
Telephone: 1-800-267-9675
Original signed by
Azmina Kanji
Manager, Quality Systems
Baxter Corporation - Canada
Appendix A: Affected Lots
Product Name: 0.9% Sodium Chloride Injection, USP
Package Size: 500 mL
Product Code: JB1323
Market Authorization Holder: Baxter Corporation
DIN: 00060208
Lot Number
Expiration Date
1
W1I14B0F
DEC22
2
W1I15B0
DEC22
3
W1I23B0
DEC22
4
W1I24B0
DEC22
5
W1I30B0
DEC22
6
W1J07B0
JAN23
7
W1J20B0
JAN23
8
W1J22B0
JAN23
9
W1J25B1
JAN23
10
W1J26B0
JAN23
11
W1J27B1
JAN23
12
W1J29B0
JAN23
13
W1K02B0
FEB23
14
W1K03B0
FEB23
15
W1K19B0
FEB23
16
W1K25B0
FEB23
17
W1K25B0F
FEB23
18
W1L02B0
MAR23
19
W1L03B0
MAR23
20
W1L09B0
MAR23
21
W1L10B0
MAR23
22
W1L10B0B
MAR23
23
W1L11B0
MAR23
24
W1L16B0
MAR23
25
W1L17B0
MAR23
26
W2A13B0
APR23
27
W2A14B0
APR23
28
W2A19B1
APR23
29
W2A20B0
APR23
30
W2A21B0
APR23
31
W2A22B0
APR23
32
W2A26B0
APR23
33
W2A29B0
APR23
34
W1E05B0
AUG22
35
W1E06B0
AUG22
36
W1E11B0
AUG22
37
W1E18B0
AUG22
38
W1E21B0
AUG22
39
W1E27B0
AUG22
40
W1F03B0
SEP22
41
W1F04B0
SEP22
42
W1F11B0
SEP22
43
W1F12B0
SEP22
44
W1F18B0
SEP22
45
W1F22B0
SEP22
46
W1F23B0
SEP22
47
W1F25B0
SEP22
48
W1F28B0
SEP22
49
W1F29B0
SEP22
50
W1F30B0
SEP22
51
W1G14B0
OCT22
52
W1G15B0
OCT22
53
W1G16B0
OCT22
54
W1G16B0B
OCT22
55
W1G20B0
OCT22
56
W1G21B0
OCT22
57
W1G29B0
OCT22
58
W1G30B0
OCT22
59
W1H13B0
NOV22
60
W1H19B0
NOV22
61
W1H20B0
NOV22
62
W1H26B0
NOV22
63
W1H27B0
NOV22
64
W1I01B0
DEC22
65
W1I03B0
DEC22
66
W1I09B0
DEC22
67
W1I10B0
DEC22
68
W1I14B0
DEC22
Product Name: Lactated Ringer’s Injection, USP
Package Size: 500 mL
Product Code: JB2323
Market Authorization Holder: Baxter Corporation
DIN: 00061085
Lot Number
Expiration Date
1
W1H04B0
NOV22
2
W1I17B0
DEC22
3
W1J28B0
JAN23
4
W1K26B0
FEB23
5
W1L22B0
MAR23
6
W2A27B0
APR23
7
W2A27B0S
APR23
8
W1E14B0
AUG22
9
W1F24B0
SEP22
Appendix B: Area or Location of Potential Leakage
In the affected lots, leaks are more likely to be found in the area shown below:
If any leakage is observed from the bags before or during treatment, stop using the product.